Cases & Deals

Allergan acquires LiRIS® program from TARIS Biomedical for $587.5 million

Clients Allergan, Inc.

Jones Day advised Allergan Inc. in the acquisition of LiRIS Biomedical, Inc. (formerly known as Taris Biomedical Inc.) and a license to the worldwide rights to TARIS Biomedical's® lead program, LiRIS®, for the treatment of interstitial cystitis / bladder pain syndrome. Allergan paid $67.5 million in cash upfront, subject to adjustments and holdbacks, and also agreed to pay up to an aggregate of $295 million in development milestone payments and up to an aggregate of $225 million in commercial milestone payments. Prior to the closing of the transaction, LiRIS spun out certain assets relating to its platform technology to a new company funded by TARIS shareholders, and such new company granted a license to LiRIS under all IP-related to the lead program.

We use cookies to deliver our online services. Details of the cookies and other tracking technologies we use and instructions on how to disable them are set out in our Cookies Policy. By using this website you consent to our use of cookies.